Barriers to the release of human tissue for clinical trials research in the UK: a national survey of cellular pathology laboratories on behalf of the National Cancer Research Institute's Cellular Molecular Pathology (CM-Path) initiative.

Aim: To survey UK cellular pathology departments regarding their attitudes and practices relating to release of human tissue from their diagnostic archives for use in clinical trial research.
Methods: A 30-item questionnaire was circulated to the National Cancer Research Institute's Cellular Molecular Pathology initiative and Confederation of Cancer Biobanks mailing lists. Responses were collected over a 10-month period from November 2016 to August 2017.
Results: 38 departments responded to the survey, the majority of which regularly receive requests for tissue for research purposes. Most requests come from academia and financial support to facilitate tissue release comes from a variety of sources. A range of practices were reported in relation to selection of the most appropriate sample to release, consent checking, costing and governance frameworks.
Conclusions: This survey demonstrates wide variation in practice across the UK and identifies barriers to release of human tissue for clinical trial research. Until we can overcome these obstacles, patient samples will remain inaccessible to research. Therefore, this study highlights the urgent need for clear and coordinated national guidance on this issue.
Competing Interests: Competing interests: KAO reports grants from the National Cancer Research Institute during the conduct of the study; grants from Leica Biosystems, grants from Qiagen, non-financial support from ThermoFisher, non-financial support from Illumina, non-financial support from Aridhia, non-financial support from Sistemic, non-financial support from BioClavis, non-financial support from Biotheranostics, outside the submitted work. CV reports other from National Cancer Research Institute CM-Path, other from NIHR Oxford Biomedical Research Centre (BRC), other from CRUK Oxford Cancer Centre, during the conduct of the study. PSM, AH, JL, JH, VS and GJT have nothing to disclose.
(© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)